



ABSTRACT OF THE DISCLOSURE

- This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula:



- in which A is a moiety of the formula



where

- the dotted line represents optional unsaturation;
 - R₁ is hydrogen or alkyl;
 - R₂ is alkyl;
 - R₄ is hydrogen, alkyl, formyl, or alkanol;
 - R₅ and R₆ are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy;
 - R₇ is hydrogen or alkyl; and
 - n is 0, 1, 2, 3, or 4;
- or a pharmaceutically acceptable salt thereof.